CD14 and melanoma: In regionally advanced melanoma patients treated with neoadjuvant Ipilimumab, circulating CD14+HLA-DRlow/− M-MDSC levels were lower at baseline but tended to increase, although not reaching statistical significance, in the relapse-free group, while frequencies in the relapsed group remained stable (110).